FDA Accepts and Grants Priority Review for AVYCAZ® (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)

- Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Intra-Abdominal Infections (cIAI), in Combination with Metronidazole -

Feb 24, 2016, 07:30 ET from Allergan plc

$countyNameToPathMap.put("sp